Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Coherus BioSciences (CHRS) Reports Q4 Loss of $1.72/Share

Coherus BioSciences Reports Second Quarter 2016 Financial and Operating Results

August 9, 2016 4:01 PM EDT

REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reported financial results and reviewed corporate events for the second quarter ended June 30, 2016.

Corporate Highlights for the Second Quarter 2016 Include:

Immunology (anti-TNF) therapeutic franchise: CHS-1420 (adalimumab (HUMIRA®) biosimilar) Received favorable decision from the Patent Trial and Review Board (PTAB) for the United States Patent and Trademark Office (USPTO) instituting Coherus' petition for Inter Partes Review (IPR) of AbbVies U.S. patent 8,889,135 (the 135 patent), 9,017,680 and 9,073,987 (patents 680 and 987, respectively), which are all related to the dosing regimen for... More